Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2019 16:17 ET | Source: Otonomy, Inc.

Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update

OTO-313 Phase 1/2 trial in tinnitus initiated; results expected in first half of 2020OTIPRIO® co-promotion agreement completed with Glenmark TherapeuticsOTIVIDEX™ Phase 3 trial in Ménière’s disease on...
May 01, 2019 07:30 ET | Source: Otonomy, Inc.

Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit

SAN DIEGO, May 01, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
April 29, 2019 16:05 ET | Source: Otonomy, Inc.

Otonomy to Report First Quarter 2019 Financial Results and Provide Corporate Update

SAN DIEGO, April 29, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
April 11, 2019 07:30 ET | Source: Otonomy, Inc.

Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus

SAN DIEGO, April 11, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
March 05, 2019 07:30 ET | Source: Otonomy, Inc.

Otonomy to Participate in Two Upcoming Investor Conferences

SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
March 04, 2019 16:18 ET | Source: Otonomy, Inc.

Otonomy Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

OTIVIDEX™ Phase 3 trial in Ménière’s disease on track for results in first half 2020 OTO-313 Phase 1/2 trial in tinnitus expected to start in second quarter of 2019OTO-413 Phase 1/2 trial in hearing...
November 06, 2018 07:30 ET | Source: Otonomy, Inc.

Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss

Society for Neuroscience Features OTO-413 Presentation as Neuroscience 2018 Hot Topic SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company...
October 30, 2018 07:30 ET | Source: Otonomy, Inc.

Otonomy Announces Multiple Presentations at Society for Neuroscience Annual Meeting including OTO-413 Presentation Selected as "Hot Topic"

SAN DIEGO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced multiple...
October 29, 2018 07:30 ET | Source: Otonomy, Inc.

Otonomy to Report Third Quarter 2018 Financial Results and Provide Corporate Update

Webcast and Conference Call to be Held at 4:30 p.m. EST on November 5, 2018 SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the...
August 01, 2018 16:05 ET | Source: Otonomy, Inc.

Otonomy to Report Second Quarter 2018 Financial Results and Provide Corporate Update

SAN DIEGO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will...

Next Page keyboard_arrow_right